康柏西普与阿柏西普治疗糖尿病视网膜病变的效果比较

Comparison of the Effect of Conbercept and Aflibercept in the Treatment of Diabetic Retinopathy

目的:比较康柏西普与阿柏西普治疗糖尿病视网膜病变(DR)患者疗效及安全性.方法:选择2020年4月—2022年4月我院收治的90例DR患者,随机分为康柏西普组(45例)与阿柏西普组(45例),均连续玻璃体腔注射3次,并随访3个月,按需再次注射.比较两组治疗前后最佳矫正视力(BCVA)、黄斑中心厚度(CMT)及随访期间再次注射次数,评价临床疗效和安全性.结果:阿柏西普组治疗1、3个月CMT小于康柏西普组(P<0.05);阿柏西普组末次随访时BCVA及差值大于康柏西普组(P<0.05);康柏西普组再次注射次数多于阿柏西普组(P<0.05).康柏西普组总有效率为80.00%,阿柏西普组总有效率为86.67%,组间比较,差异无统计学意义(P>0.05).阿柏西普组中有1例出现眼压升高,其余患者均未出现眼部及全身不良反应.结论:康柏西普与阿柏西普治疗DR总体安全有效,但阿柏西普对黄斑水肿和视力的改善可能更快,并且需要注射的次数更少.

Objective:To compare the efficacy and safety of conbercept and aflibercept in the treatment of diabetic retinopathy(DR).Methods:Ninety patients with DR admitted to our hospital from April 2020 to April 2022 were randomly divided into conbercept group(45 cases)and aflibercept group(45 cases).All patients were injected into the vitreous cavity three times continuously and followed up for 3 months.The best corrected visual acuity(BCVA),central macular thickness(CMT)before and after treatment and the number of re-injections during follow-up were compared between the two groups to evaluate the clinical efficacy and safety.Results:The CMT of the aflibercept group was lower than that of the conbercept group at 1 and 3 months(P<0.05).The BCVA and difference at the last follow-up in the aflibercept group were greater than those in the conbercept group(P<0.05).The number of reinjections in the conbercept group was more than that in the aflibercept group(P<0.05).The total effective rate was 80.00%in the conbercept group and 86.67%in the afibercept group.There was no significant difference between the two groups(P>0.05).In the aflibercept group,1 case had elevated intraocular pressure,and the remaining patients had no ocular and systemic adverse reactions.Conclusion:Conbercept and aflibercept are generally safe and effective in the treatment of DR,but aflibercept may improve macular edema and vision faster and require fewer injections.